Dr. Vinod Pullarkat

Hematology
209 Fair Oaks Ave, 
South Pasadena, CA 
209 Fair Oaks Ave, 
South Pasadena, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vinod Pullarkat is a Hematologist in South Pasadena, California. Dr. Pullarkat is rated as an Experienced provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 209 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
A Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drugs: Sabatolimab, Azacitidine, Venetoclax
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2023
Intervention Type: Other, Drug
Study Drug: 8-Chloroadenosine
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
Enrollment Status: Terminated
Publish Date: May 25, 2023
Intervention Type: Biological
Study Drugs: Thrombosomes, Liquid-Stored Platelets
Study Phase: Phase 2
View 5 Less Clinical Trials

205 Total Publications

Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
Journal: Leukemia & lymphoma
Published: August 05, 2025
Similar Doctors
Distinguished in Drug-Induced Thrombocytopenia
Dr. Anas Raowas
Hematology Oncology | Hematology | Oncology
Distinguished in Drug-Induced Thrombocytopenia
Dr. Anas Raowas
Hematology Oncology | Hematology | Oncology

Los Angeles Hematology-Oncology Medical Group

4500 Brockton Ave, Suite 107, 
Riverside, CA 
 (45.1 miles away)
951-276-2760
Languages Spoken:
English
See accepted insurances

Anas Raowas is a Hematologist Oncology specialist and a Hematologist in Riverside, California. Dr. Raowas is rated as an Advanced provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Drug-Induced Thrombocytopenia, Thrombocytopenia, Anemia, and Essential Thrombocythemia.

Advanced in Drug-Induced Thrombocytopenia
Dr. Baijia Jiang
Hematology Oncology | Hematology | Oncology
Advanced in Drug-Induced Thrombocytopenia
Dr. Baijia Jiang
Hematology Oncology | Hematology | Oncology

Los Angeles Hematology-Oncology Medical Group

1801 W Romneya Dr, Suite 203, 
Anaheim, CA 
 (22.2 miles away)
714-999-1465
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Baijia Jiang is a Hematologist Oncology specialist and a Hematologist in Anaheim, California. Dr. Jiang is rated as an Advanced provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. Her top areas of expertise are Drug-Induced Thrombocytopenia, Idiopathic Neutropenia, Iron Deficiency Anemia, and Thrombocytopenia.

Advanced in Drug-Induced Thrombocytopenia
Dr. Samuel W. Chung
Hematology Oncology | Oncology | Hematology
Advanced in Drug-Induced Thrombocytopenia
Dr. Samuel W. Chung
Hematology Oncology | Oncology | Hematology

City Of Hope Medical Foundation

301 W Huntington Dr, Suite 400, 
Arcadia, CA 
 (6.2 miles away)
626-218-9840
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Samuel Chung is a Hematologist Oncology specialist and an Oncologist in Arcadia, California. Dr. Chung is rated as a Distinguished provider by MediFind in the treatment of Drug-Induced Thrombocytopenia. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pullarkat's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 31 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile